financetom
Business
financetom
/
Business
/
Acadia Healthcare Q4 Adjusted Earnings Decline, Revenue Rises -- Shares Fall After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Acadia Healthcare Q4 Adjusted Earnings Decline, Revenue Rises -- Shares Fall After Hours
Feb 27, 2025 2:28 PM

05:03 PM EST, 02/27/2025 (MT Newswires) -- Acadia Healthcare ( ACHC ) reported Q4 adjusted diluted earnings Thursday of $0.64, down from $0.85 a year earlier.

Analysts polled by FactSet expected $0.71.

Revenue for the quarter ended Dec. 31 was $774.2 million, up from $742.8 million.

Analysts surveyed by FactSet expected $779 million.

The company said it expects Q1 revenue of $765 million to $775 million.

Analysts polled by FactSet expect $820.6 million.

For the full year 2025, the company expects adjusted EPS of $2.50 to $2.80 on $3.3 billion to $3.4 billion in revenue.

Analysts surveyed by FactSet expect $3.35 on revenue of $3.43 billion.

Additionally, Acadia said its board authorized a share repurchase program of up to $300 million for the company's outstanding common stock.

Shares of Acadia Healthcare ( ACHC ) were down over 14% in after-hours trading.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Top Premarket Gainers
Top Premarket Gainers
Jul 25, 2024
07:34 AM EDT, 07/25/2024 (MT Newswires) -- BloomZ ( BLMZ ) shares surged 24% pre-bell Thursday, rebounding from Wednesday's slump. MIRA Pharmaceuticals ( MIRA ) shares surged 43% after the company said preclinical data showed the potential benefits of Ketamir-2, a treatment candidate for neurological and neuropsychiatric disorders. Viking Therapeutics ( VKTX ) shares increased 18% after the company reported...
AbbVie lifts annual profit forecast on strong immunology drug sales
AbbVie lifts annual profit forecast on strong immunology drug sales
Jul 25, 2024
(Reuters) - AbbVie ( ABBV ) raised its annual profit forecast on Thursday as strong sales of its key immunology drugs, including Humira, helped it beat Wall Street expectations for the second quarter. Sales of Humira, once the world's top-selling drug, have been declining since its close copies, or biosimilars, hit the U.S. market. There are now 10 Humira biosimilars...
Masco's Q2 Adjusted Net Income Rises, Sales Fall; 2024 Adjusted EPS Outlook Revised
Masco's Q2 Adjusted Net Income Rises, Sales Fall; 2024 Adjusted EPS Outlook Revised
Jul 25, 2024
07:38 AM EDT, 07/25/2024 (MT Newswires) -- Masco ( MAS ) reported Q2 adjusted net income Thursday of $1.20 per share, up from $1.19 a year earlier. Analysts polled by Capital IQ expected $1.18. Net sales for the quarter ended June 30 were $2.09 billion, down from $2.13 billion a year earlier. Analysts surveyed by Capital IQ expected $2.10 billion....
TechnipFMC Q2 Adjusted Earnings, Revenue Increase
TechnipFMC Q2 Adjusted Earnings, Revenue Increase
Jul 25, 2024
07:40 AM EDT, 07/25/2024 (MT Newswires) -- TechnipFMC ( FTI ) reported Q2 adjusted earnings Thursday of $0.43 per diluted share, up from $0.10 a year earlier. Analysts polled by Capital IQ expected $0.31. Revenue for the quarter ended June 30 was $2.33 billion, up from $1.97 billion a year earlier. Analysts surveyed by Capital IQ expected $2.23 billion. TechnipFMC...
Copyright 2023-2026 - www.financetom.com All Rights Reserved